5.01
price down icon6.53%   -0.35
pre-market  Pre-market:  4.01   -1.00   -19.96%
loading
Amylyx Pharmaceuticals Inc stock is traded at $5.01, with a volume of 547.09K. It is down -6.53% in the last 24 hours and up +36.89% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$5.36
Open:
$5.36
24h Volume:
547.09K
Relative Volume:
0.70
Market Cap:
$376.83M
Revenue:
$380.79M
Net Income/Loss:
$49.27M
P/E Ratio:
7.1571
EPS:
0.7
Net Cash Flow:
$10.68M
1W Performance:
+18.44%
1M Performance:
+36.89%
6M Performance:
-6.00%
1Y Performance:
+184.66%
1-Day Range:
Value
$4.983
$5.41
1-Week Range:
Value
$4.28
$5.465
52-Week Range:
Value
$1.575
$7.27

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name
Name
Amylyx Pharmaceuticals Inc
Name
Phone
617-683-0917
Name
Address
43 THORNDIKE STREET, CAMBRIDGE
Name
Employee
123
Name
Twitter
Name
Next Earnings Date
2025-03-04
Name
Latest SEC Filings
Name
AMLX's Discussions on Twitter

Compare AMLX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AMLX
Amylyx Pharmaceuticals Inc
5.01 376.83M 380.79M 49.27M 10.68M 0.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-07-25 Upgrade Mizuho Neutral → Outperform
Nov-18-24 Upgrade Robert W. Baird Neutral → Outperform
Oct-23-24 Upgrade BofA Securities Neutral → Buy
Mar-18-24 Downgrade Mizuho Buy → Neutral
Mar-11-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-11-24 Downgrade Robert W. Baird Outperform → Neutral
Mar-08-24 Downgrade Evercore ISI Outperform → In-line
Mar-08-24 Downgrade Goldman Buy → Neutral
Jan-03-24 Initiated Robert W. Baird Outperform
Dec-12-23 Initiated Deutsche Bank Buy
Jul-24-23 Upgrade Goldman Neutral → Buy
Mar-31-23 Initiated Mizuho Buy
Jan-05-23 Initiated BofA Securities Buy
May-25-22 Initiated Citigroup Buy
Apr-01-22 Downgrade Goldman Buy → Neutral
View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 27, 2025

Amylyx Pharma Gearing Up For FDA Decision - RTTNews

Apr 27, 2025
pulisher
Apr 25, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Apr 25, 2025
pulisher
Apr 25, 2025

Stock Surge: Amylyx Pharmaceuticals Inc (AMLX) Closes at 3.00, Marking a -9.09 Increase/Decrease - DWinneX

Apr 25, 2025
pulisher
Apr 24, 2025

What is the investor’s view on Amylyx Pharmaceuticals Inc (AMLX)? - uspostnews.com

Apr 24, 2025
pulisher
Apr 23, 2025

Recent Insider Activity Could Benefit Amylyx Pharmaceuticals Inc (AMLX) - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Amylyx Pharmaceuticals Inc Shares Are Up 148.48% Since The Beginning Of The Year - Marketing Sentinel

Apr 23, 2025
pulisher
Apr 23, 2025

Amylyx Pharmaceuticals Inc (AMLX) Stock: A Year of Market Fluctuations - investchronicle.com

Apr 23, 2025
pulisher
Apr 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com

Apr 20, 2025
pulisher
Apr 18, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com

Apr 18, 2025
pulisher
Apr 17, 2025

Q1 Earnings Forecast for AMLX Issued By Leerink Partnrs - Defense World

Apr 17, 2025
pulisher
Apr 16, 2025

Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey

Apr 16, 2025
pulisher
Apr 15, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - markets.businessinsider.com

Apr 15, 2025
pulisher
Apr 15, 2025

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by American Century Companies Inc. - Defense World

Apr 15, 2025
pulisher
Apr 15, 2025

American Century Companies Inc. Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter

Apr 15, 2025
pulisher
Apr 15, 2025

Wellington Management Group LLP Acquires Shares of 209,708 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter

Apr 15, 2025
pulisher
Apr 14, 2025

Wellington Management Group LLP Makes New $793,000 Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

Apr 13, 2025
pulisher
Apr 12, 2025

Amylyx upgraded at Mizuho on potential of lead asset - MSN

Apr 12, 2025
pulisher
Apr 10, 2025

First subject dosed in Amylyx’s Phase I trial of ALS therapy - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com

Apr 10, 2025
pulisher
Apr 09, 2025

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis - BioSpace

Apr 09, 2025
pulisher
Apr 09, 2025

Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Breakthrough ALS Treatment Enters Human Trials: Amylyx Targets New Disease Mechanism - Stock Titan

Apr 09, 2025
pulisher
Apr 08, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - markets.businessinsider.com

Apr 08, 2025
pulisher
Apr 08, 2025

Is Now The Time To Buy Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Stock? - stocksregister.com

Apr 08, 2025
pulisher
Apr 08, 2025

Amylyx Pharmaceuticals (NASDAQ:AMLX) Rating Increased to Outperform at Mizuho - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Mizuho Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq

Apr 07, 2025
pulisher
Apr 07, 2025

Amylyx stock upgraded at Mizuho on lead asset (AMLX:NASDAQ) - Seeking Alpha

Apr 07, 2025
pulisher
Apr 07, 2025

Mizuho lifts Amylyx stock rating, doubles price target to $7 - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Mizuho lifts Amylyx stock rating, doubles price target to $7 By Investing.com - Investing.com UK

Apr 07, 2025
pulisher
Apr 06, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - markets.businessinsider.com

Apr 06, 2025
pulisher
Apr 06, 2025

Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire

Apr 06, 2025
pulisher
Apr 05, 2025

Don't Ignore The Insider Selling In Amylyx Pharmaceuticals - simplywall.st

Apr 05, 2025
pulisher
Apr 03, 2025

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

Apr 03, 2025
pulisher
Apr 03, 2025

Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking - simplywall.st

Apr 03, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals Executives Unload Massive Stock Shares! - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock By Investing.com - Investing.com South Africa

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Amylyx Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView

Apr 02, 2025

Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Cap:     |  Volume (24h):